Recent advances in the pharmacogenetics of cancer chemotherapy

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 6, 2002, Pages 565-571

  Watters, James W ^a   McLeod, Howard L ^a,b,c  

^a Department of Medicine ^*  (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

Author keywords

Cancer; Genetics; Genomics; Microarray; Molecular therapeutics; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARBOXYLESTERASE; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GLUTATHIONE TRANSFERASE; IRINOTECAN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DNA REPAIR; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INDIVIDUALIZATION; LEUKOPENIA; LUNG CANCER; NEUTROPENIA; NUCLEOTIDE METABOLISM; PHARMACOGENETICS; REVIEW;

ANIMALS; HUMANS; NEOPLASMS; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036931648     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med (2001) 345(2):144-145.
2. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol (2001) 19(18):3801-3807.
3. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. J Am Med Assoc (2001) 286(18):2270-2279.
4. Lennard L, Van Loon J, Weinshilboum R: Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther (1989) 46(2):149-154.
5. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM: Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr (1991) 119(6):985-989.
6. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM: Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med (1998) 129(9):716-718.
7. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 91(23):2001-2008.
8. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 12(11):2248-2253.
9. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res (1993) 53(22):5433-5438.
10. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB: Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res (1999) 5(8):2006-2011.
11. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest (1988) 81(1):47-51.
12. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (2001) 15(1 Suppl 2):21-26.
13. Van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH: Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res (2001) 7(5):1149-1153.
14. Innocenti F, Ratain MJ: Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer (2002) 38(5):639-644.
15. Wei X, McLeod HL, Mcmurrough J, Gonzalez FJ, Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest (1996) 98(3):610-615.
16. Gonzalez FJ, Fernandez-Salguero P: Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. Trends Pharmacol Sci (1995) 16(10):325-327.
17. Ridge SA, Sludden J, Brown O, Robertson L, Wei X, Sapone A, Fernandez-Salguero PM, Gonzalez FJ, Vreken P, van Kuilenburg AB, van Gennip AH, McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br J Clin Pharmacol (1998) 46(2):151-156.
18. Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer (1998) 77(3):497-500.
19. Mcleod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ: Nomenclature for human DPYD alleles. Pharmacogenetics (1998) 8(6):455-459.
20. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res (2001) 7(9):2832-2839.
21. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics (2000) 10(3):217-223.
22. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gone and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 55(7):1407-1412.
23. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 15(10):3223-3229.
24. Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S: Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res (1987) 15(3):1259-1270.
25. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct (1995) 20(3):191-197.
26. Marsh S, Ameyaw M, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL: Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat (2000) 16(6):528.
27. Luo HR, Lu XM, Yao YG, Horie N, Takeishi K, Jorde LB, Zhang YP: Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet (2002) 40(1-2):41-51.
28. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV: Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res (2001) 7(12):4096-4101.
29. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1(1):65-70.
30. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol (2001) 19(6):1779-1786.
31. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol (2001) 19(2):383-386.
32. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res (1994) 54(14):3723-3725.
33. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest (1998) 101(4):847-854.
34. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim, S, Di Rienzo A, Ratain MJ: Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 65(5):576-582.
35. Fisher MB, Vandenbranden M, Findlay K, Burchell B, Thummel KE, Hall SD, Wrighton SA: Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: Relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics (2000) 10(8):727-739.
36. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA (1998) 95(14):8170-8174.
37. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J (2002) 2(1):43-47.
38. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis. Cancer Res (2000) 60(24):6921-6926.
39. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeraderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res (2001) 61(24):8654-8658.
40. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, Bell DA: XPD polymorphisms: Effects on DNA repair proficiency. Carcinogenesis (2000) 21(4):551-555.
41. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res (2001) 61(4):1354-1357.
42. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res (2001) 21(4B):3075-3079.
43. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA: XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res (1999) 59(11):2557-2561.
44. Zhang K, Mack P, Wong KD: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol (1998) 12(4):871-882.
45. Board PG, Baker RT, Chelvanayagam G, Jermiin LS: Zeta, a novel class of glutathione transferases; in a range of species from plants to humans. Biochem J (1997) 328(Pt 3):929-935.
46. Chao CC, Huang YT, Ma CM, Chou WY, Lin-Chao S: Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol (1992) 41(1):69-75.
47. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst (2002) 94(12):936-942.
48. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis (1998) 19(2):275-280.
49. Chicurel ME, Dalma-Weiszhausz DD: Microarrays in pharmacogenomics - advances and future promise. Pharmacogenomics (2002) 3(5):589-601.